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AEDHashimoto's encephalopathy is deﬁned by the coexistence of encephalopathy and antithyroid antibodies.We re-
port two cases of adult-onset temporal lobe epilepsy with subacute cognitive decline, high titers of antithyroid
antibodies, multi-antiepileptic drug hypersensitivity, and good response to immunomodulatory treatment. The
relevance of multidrug hypersensitivity in the setting of adult-onset epilepsy and the importance of searching
for autoimmune causes for epilepsy are discussed.
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There has been increasing interest in an immune-based etiology
for adult-onset epilepsy [1]. One of the autoimmune disorders linked
to epilepsy is Hashimoto's encephalopathy. This disorder, which is
also called steroid-responsive encephalopathy associated with auto-
immune thyroiditis (SREAT), was ﬁrst described by Brain et al. [2] as
an association between antithyroid antibodies and encephalopathy.
Its prevalence is estimated to be 2:100,000, with a predominance of
females in their 5th–6th decades of life and with varying presentations,
such as stroke-like events or behavioral changeswith orwithout epilep-
sy [3]. One of the proposed mechanisms for antiepileptic drug hyper-
sensitivity is also an immune-mediated process [4]. We report two
cases of Hashimoto's encephalopathy manifesting as adult-onset tem-
poral epilepsy, cognitive decline, and multi-antiepileptic drug (AED)
hypersensitivity.
2. Case 1
A 60-year-old female with amedical history remarkable for satisfac-
torily treated hypothyroidism and dyslipidemia was ﬁrst admittedy, Tel-Aviv Sourasky Medical
c.Open access under CC BY-NC-ND licebecause of a dissociative event that lasted for 1 h, in which she de-
scribed viewing herself outside of her body. No abnormal movements,
amnesia, focal neurological deﬁcits, fever, or systemic signs were
noted. Her neurological examination was normal, as were her head
computerized tomogram (CT) and routine laboratory workup (com-
plete blood count, electrolytes, kidney and liver function, and thyroid
functions). An electroencephalogram (EEG) demonstrated interictal
right frontotemporal epileptiform activity. A lumbar puncture demon-
strated high opening pressure (285 mm H2O) with normal content
and no detectable oligoclonal bands. She was discharged from the hos-
pital on a regimen of lamotrigine treatment (25 mg/day, with instruc-
tions for a slow, gradual increase in the dosage). She returned one
week later because of a severe rash over her entire body for which she
received prednisone (60 mg/day) and antihistamines (chlorphenir-
amine maleate, 2 mg bid). The lamotrigine was discontinued, and car-
bamazepine (100 mg bid, with instructions of a 100-mg/week
increase) was started. Two weeks later, she presented with worsening
of the rash and reported that she had stopped the steroid therapy with-
out tapering down the dose as instructed. She was admitted to the hos-
pital and treated with IV hydrocortisone and then oral prednisone
(1 mg/kg), following a stepwise decrease of the steroid dosage. The car-
bamazepine was replaced by valproate (with an initial dosage of
250 mg bid). The valproate dose was increased gradually, but the AED
treatment was switched to levetiracetam (with an initial oral dosage
of 250 mg bid) when she developed thrombocytopenia (down to
25,000/ml) that began 48 h after the ﬁrst dosage. Her condition subse-
quently improved, and she was discharged, ending a total of 17 days
with either IV or oral steroid therapy. She was instructed to reduce
the steroid treatment for several weeks until it was stopped.nse.
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because of cognitive changes, insomnia, and agitation. A brain magnetic
resonance imaging (MRI) scan demonstrated asymmetry of the hip-
pocampi without abnormal signal or any other pathological ﬁnding.
Video-EEG monitoring revealed multiple right temporal electroen-
cephalographic seizures during the night. Serology results for HIV,
hepatitis B and C, VDRL, TPHA, and HHV6 were all negative. Thyroid
function was normal. A routine rheumatologic workup and testing for
antiphospholipid antibodies were negative. Blood samples were sent
to test neoplastic markers as well as the following paraneoplastic anti-
bodies: anti-Yo (anti-Purkinje cell cytoplasmic antibody, associated
with ovarian and breast cancer) and anti-Hu (antineuronal nuclear an-
tibody type I, associated with small-cell lung cancer). The result of a full
gynecological examination including ultrasonography andmammogra-
phy was normal. She also underwent colonoscopy, which revealed a
single polypwhose histologywas consistent with high-grade dysplastic
adenoma, aswell as chest-abdominal and pelvic CT, the results of which
were normal. The paraneoplastic laboratory results turned out to be
normal. Thus, the only positive ﬁnding was extremely high titers of
antithyroglobulin (5318 U/ml) and of antithyroid peroxidase (TPO,
N3000 U/ml), corresponding to the diagnosis of Hashimoto's encepha-
litis. Since steroid therapy had been previously administered for the di-
agnosis of severe drug eruption and found to be ineffective for the
clinical presentation of Hashimoto's encephalitis as cognitive changes
were added to the clinical picture, she was treated with plasma ex-
change (5 courses over 10 days). Although no clinical improvement
was noted at ﬁrst, EEG monitoring demonstrated signiﬁcant improve-
ment after 14 days, with only one EEG-veriﬁed electroencephalograph-
ic seizure per night, compared to 3–4 electroencephalographic seizures
per night before the plasma exchange (Fig. 1E). Cognitive assessment
(Montreal Cognitive Assessment [MoCA]) performed before and after
plasma exchange revealed a mild cognitive impairment (24/30, mainly
attentiondeﬁcit andmemory) that improvedby twopoints after receiv-
ing treatment (Figs. 1A–D). She was discharged with the recommenda-
tion of continued ambulatory immunomodulatory treatment withFig. 1. Timeline of Case 1. Clock drawing as a sample of the cognitive assessment before plasma
effects of the treatment) (B), and two (C) and ﬁve (D)months following plasma exchange, with
representative right temporal encephalographic seizure was recorded during a night's sleep. L
gabapentin, CLB — clobazam, PRD — prednisone, PE — plasma exchange, MoCA —Montreal Coplasma exchange. There was no further improvement in the MoCA
score at the 1-month follow-up, but the patient reported that she felt
that her cognitive function improved. At that time, she complained of
side effects related to the AED treatment (mainly fatigue). She was of-
fered intravenous immunoglobulin (IVIg) treatmentwhich she refused.
One month later, she returned for another scheduled outpatient visit,
after having stopped all antiepileptic therapy, and felt that she had
returned to her regular levels of function, an observation supported by
her spouse. She refused to undergo another EEG examination and
blood tests. Further follow-up demonstrated clinical and electroen-
cephalographic relapses every few months, with elevated antithyroid
antibodies at similar levels, which responded to an additional course
of plasma exchangewith improvement in her clinical state. Our sugges-
tion was therefore to continue treatment with plasma exchange on a
regular basis, and because of the good response, there was no need for
more aggressive immunomodulatory treatment.3. Case 2
A 70-year-old womanwith a past medical history of well-controlled
hypothyroidism and hypertension was admitted to our service because
of eventsmanifested by a detachment fromher surroundings lasting for
about 1 min each that had started 18 months earlier. Some of these
beganwith a scream, following a tonic phasewith loss of consciousness.
Her EEG and head CT were unremarkable, and oral lamotrigine treat-
ment beginning at 25 mg/day (with instructions for a slow increase)
was initiated. A hypersensitivity reaction presenting as a rash all over
her body appeared about 10 days later, and the treatmentwas switched
to oral valproate (beginning at a dosage of 250 mg bid with a slow in-
crease). A brain MRI scan demonstrated hyperintense periventricular
lesions, suggesting a vascular basis. The valproate treatment did not
lead to any signiﬁcant reduction in the seizure frequency, and oral
topiramate (beginning at 25 mg/day) was added. She was then hospi-
talized because of two seizure events, each lasting up to 15 min, inexchange (A), after plasma exchange (notice the relative worsening, attributed to the side
increasingly better performance. The clockwas fully accurate only on the last test. (E) This
MT — lamotrigine, CBZ — carbamazepine, VPA — valproate, LEV — levetiracetam, GBP —
gnitive Assessment.
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companied by abnormal movements or loss of consciousness.
The neurological examination on admission was notable for disori-
entation and evident cognitive abnormality as demonstrated by a
MoCA score of 12/30 (speciﬁcally, abnormal serial seven, immediate
memory, and abstraction). She exhibited mild extrapyramidal signs
and ﬂapping tremor. An EEG showed focal left frontal intermittent
slowing. The lumbar puncture had normal opening pressure and con-
tent, and the tau protein level was within the normal range. Routine
blood work revealed polycythemia and mild leukocytosis, while the
electrolyte levels, liver and kidney functions, thyroid functions, C-
reactive protein levels, and neoplastic markers were all normal. Routine
rheumatologic tests and antiphospholipid antibodies were normal. The
only positive relevant result was very high titers of antithyroglobulin
(5564 U/ml) and antithyroidmicrosomal antibody (N3000 U/ml). A re-
peated brainMRI revealed progressivemild atrophy and a hyperintense
temporal cortical signal restricted in diffusion. Methylprednisolone (IV,
500 mg/day for 5 days) was administered, and the valproate was
switched to levetiracetam (500 mg bid) because of extrapyramidal
side effects. She was released from the hospital with instructions to
taper the oral prednisone dosage. She returned three weeks later with
an allergic drug reaction, manifested through a skin rash and pruritus,
while being treated with 30-mg prednisone (during the tapering
down) that was attributed to the levetiracetam. Gabapentinwas started
in addition to topiramate with disappearance of the rash. The repeated
MoCA score was 16/30, suggesting mild improvement. At a follow-up
visit several months later, the patient and her family reportedFig. 2. Timeline of Case 2. Clock drawing as a sample of the cognitive assessment beforemethylp
(C) and 7 months (D) following treatment, that begun 5 month after the ﬁrst admission. These
agnosis (E) and 2 months later (F), showing a progressive periventricular hyperintense signal w
topiramate, GBP — gabapentin, MET —methylprednisolone, PRD— prednisone, MoCA —Montsigniﬁcant improvement. She had returned to her usual levels of func-
tion and normal lifestyle, and she was seizure-free. Although we did
not notice a prominent cognitive improvement, she did return to her
baseline daily function, and, therefore, we did not suggest further
immunomodulatory treatment, except for low prednisone dosage
(10 mgdaily). Furthermeasurement of the antithyroid antibodies dem-
onstrated a marked reduction (anti-TPO: 349 U/ml, antithyroglobulin:
461 U/ml, Fig. 2).
4. Discussion
We describe here two cases of adult-onset temporal lobe epilepsy
with cognitive decline and antithyroid antibodies (Hashimoto's enceph-
alopathy), as well as multi-AED hypersensitivity and clinical improve-
ment with immunomodulatory therapy. Hashimoto's encephalopathy
has been previously linked to new-onset epilepsy [5–7] and to cognitive
changes [6–8]. However, to our knowledge, this is the ﬁrst report
describing multi-AED hypersensitivity coexisting with Hashimoto's
encephalopathy.
Hashimoto's encephalopathy is a controversial syndrome, since
it is deﬁned as an association of autoantibodies (anti-TPO and
antithyroglobulin) and encephalopathy, a weak connection between
two common entities without any known causal relationship. Notably,
antithyroid antibodies are common (over 10%) in the healthy population
[9]. The mechanism of Hashimoto's encephalitis is unclear. Proposed
pathogenesis includes autoimmune central nervous system (CNS) vas-
culitis and an autoimmune reaction to antigens shared by the thyroidrednisolone treatment (A), immediately after the steroid pulse therapy (B), and onemonth
drawings demonstrate progressive improvement. T2 FLAIR axial section at the time of di-
ith increasing atrophy. LMT— lamotrigine, VPA— valproate, LEV— levetiracetam, TPM—
real Cognitive Assessment.
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symptoms and signs, including behavioral changes, confusion, cognitive
decline, epileptic seizures, and stroke-like episodes. There is little evi-
dence for delineating the relevant target of antithyroid antibodies in
Hashimoto's encephalopathy, although Blanchin et al. demonstrated
how anti-TPO antibodies adhere to human astrocytes and monkey-
derived cerebellar slices, andOchi et al. reportedneuronal alpha enolase
as a target for antithyroid autoantibodies [10,11].
Hashimoto's encephalopathy is probably an immune-based syn-
drome, not only because of its correlation with autoantibodies but also
because of its response to immune-mediated treatment. It is possible
that the antithyroid antibodies are markers of a predisposition to the
syndrome and not necessarily active participants in the encephalopath-
ic process [3]. Multiple drug hypersensitivity is also an immune-
mediated process. One research study demonstrates that patients with
multidrug hypersensitivity have a subpopulation of regulatory T-cells
which are in a preactivation state, as opposed to healthy controls [12].
Another recent study demonstrated how speciﬁc human leukocyte an-
tigens (HLAs) known to predispose to speciﬁc drug reactions (e.g., for
carbamazepine) activate the immunological system when exposed to
the drug [13]. However, no connection between multidrug hypersensi-
tivity and antithyroid autoantibodies has been reported to date. These
case reports are intended to raise the level of awareness on immune-
based epilepsy and/or dementia, especially since these entities may
respond to immunomodulatory therapies [8,14]. Both of our reported
patients showed improvement following treatment by steroids or plas-
ma exchange. We suggest that an immune-based etiology should be
considered in the differential diagnosis of patients who present with
adult-onset temporal epilepsy, especially in patients with idiosyncratic
drug reactions.Acknowledgment
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